Drug Type Fusion protein |
Synonyms PDL1-IL15 Affimer® fusion proteins |
Target |
Mechanism IL-2R modulators(Interleukin-2 receptor modulators), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 01 Dec 2023 |